The chairman of a pan-European pharma group says he is still optimistic that a Brexit deal can be struck, despite the head of the European Council rejecting British plans for future alignment.
Dr Fiona Marshall joins MSD from Sosei from Heptares, the UK biotech company she co-founded more than a decade ago, and which was acquired by Sosei in 2015.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
